Takeda stock gains on FDA approval for new blood cancer drug
Published on 09/01/2026 at 22:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Takeda Pharmaceutical Company (ISIN JP3730800003) stock is benefiting from fresh pipeline momentum after the U.S. Food and Drug Administration approved its new polycythemia vera drug Mimrylo, with the American depositary shares recently around 18.00 USD as of August 31, 2026 on CBOE data.
FDA approval adds a new growth driver
According to a report by Jiho on September 1, 2026, the FDA approved Mimrylo (rusfertide) on August 28, 2026 to treat erythrocytosis in adults with polycythemia vera, a type of blood cancer.
A separate overview from DelveInsight on September 1, 2026 highlights Mimrylo as one of Takeda's next generation growth drivers, underlining management's focus on specialty hematology and oncology.
Recent quarterly figures and margin trends
Takeda reported its fiscal year 2026 first quarter results for the period ending June 30, 2026, with details summarized in an earnings report referenced by Zonebourse.
For investors, profitability trends are central. A financial overview compiled by Zonebourse shows that Takeda's EBITDA margin for fiscal year 2025 improved to 24.10 percent, up from 22.09 percent in fiscal year 2024, while the EBIT margin rose to 7.48 percent from 5.02 percent over the same period.
The same dataset indicates that the EBITDA margin continued to strengthen toward 25.08 percent in fiscal year 2026, suggesting a roughly 3 percentage point improvement versus fiscal year 2024 as the company integrates past acquisitions and focuses on higher margin innovative therapies.
Stock performance and market view
Market data compiled by MarketBeat show that Takeda's NYSE-listed shares traded at 15.59 USD on January 1, 2026 and recently around 18.37 USD, representing a gain of about 17.9 percent year to date as of September 1, 2026.
Zonebourse's quotation page for CBOE lists a last price of 18.00 USD for Takeda on August 31, 2026, with a daily variation of minus 0.22 percent and a five-day change of minus 1.40 percent, while the performance since the beginning of the year is shown at plus 15.50 percent, illustrating how the recent advance has come with short term consolidation.
For investors in Europe, Takeda is also tradable via its American depositary shares on CBOE and NYSE, allowing DACH-based investors with access to U.S. venues to participate in the pipeline-led story without a direct Tokyo listing.
Takeda stock and key figures at a glance
Use our thematic overview and Takeda's own investor relations material to explore detailed financials, guidance and pipeline disclosures beyond the headline numbers.
Mimrylo expands Takeda's hematology portfolio
Mimrylo (rusfertide) targets erythrocytosis in polycythemia vera, a chronic blood cancer characterized by elevated red blood cell levels and a heightened risk of thrombosis, making effective control of hematocrit clinically important for patients.
By securing FDA approval for Mimrylo on August 28, 2026, Takeda adds an additional hematology product to its lineup, complementing existing therapies and reinforcing its strategy to grow in rare diseases and oncology segments with differentiated mechanisms of action.
Takeda stock price context for September 2026
Based on the CBOE quotation page and MarketBeat data, Takeda stock closed at 18.00 USD on CBOE on August 31, 2026, and traded at about 18.37 USD on NYSE as of intraday September 1, 2026, keeping it comfortably above the opening level of 15.59 USD at the start of fiscal 2026.
Takeda key data
- Company: Takeda Pharmaceutical Company Limited
- ISIN: JP3730800003
- Ticker: TAK
- Trading venue: NYSE ADR and CBOE
- Price (as of August 31, 2026): 18.00 USD
- Market capitalization: Not specified in available same-day sources
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: Listed in major Japan indices via primary Tokyo listing
